TAS-102，结直肠癌领域首款“心脏耐受性良好”的氟嘧啶类药物？
TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape?
作者信息
Petrelli Fausto, Barni Sandro, Bertocchi Paola, Zaniboni Alberto
机构信息
Department of Oncology, Division of Medical Oncology, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy.
Oncology Department, Fondazione Poliambulanza, Via Bissolati 57, 25100, Brescia, Italy.
出版信息
BMC Cancer. 2016 Jul 4;16:386. doi: 10.1186/s12885-016-2409-8.
BACKGROUND
Cardiotoxicity in the form of cardiac arrhythmia, myocardial infarction, and angina-like symptoms are not rare complications of fluoropyrimidines as 5-Fluorouracil (5FU) and capecitabine.
DISCUSSION
Tas-102, a novel oral fluoropyrimidine, was recently approved by FDA for the treatment of advanced and refractory colorectal cancer. Its unique mechanism of action doesn't seem linked with cardiotoxicity in clinical trials reported so far. TAS 102 may represent one of the drugs of choice for patients with advanced colorectal cancer with cardiac disease. This intriguing and clinically relevant issue is briefly examined.
背景
心律失常、心肌梗死和心绞痛样症状等形式的心脏毒性是氟嘧啶（如5-氟尿嘧啶（5FU）和卡培他滨）并不罕见的并发症。
讨论
新型口服氟嘧啶Tas-102最近被美国食品药品监督管理局（FDA）批准用于治疗晚期和难治性结直肠癌。在目前报道的临床试验中，其独特的作用机制似乎与心脏毒性无关。TAS 102可能是患有心脏病的晚期结直肠癌患者的首选药物之一。本文简要探讨了这个有趣且与临床相关的问题。
Zotero 插件